Interferon-free Sofosbuvir containing treatment regimens in a real-life cohort of chronic Hepatitis C patients with cirrhosis

Interferon‐free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses

“…There is a great need for effective anti‐viral therapy regimens in patients with clinically significant portal hypertension, as this patient group is at considerable risk for liver‐related events. Although evidence for IFN‐free regimens is very limited in patients with clinically significant portal hypertension, these treatments have already been prescribed in the USA or have been used within named patient programmes in Europe . Moreover, health insurance providers in many European countries currently restrict the access to these regimens to patients with advanced liver fibrosis for economical reasons.…”

“…Moreover, health insurance providers in many European countries currently restrict the access to these regimens to patients with advanced liver fibrosis for economical reasons. As access to these regimens steadily increases, treatment rates are likely to continue to rise in the near future . Thus, in this patient population, clinical routine currently surpasses clinical trials, emphasising the importance of studies utilising the emerging real‐life data.…”